Clinical Trial

A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single-arm, multicenter, open-label clinical study evaluating the efficacy and safety of axicabtagene ciloleucel injection manufactured by an automated cell preparation process in adult subjects with relapsed or refractory large B-cell lymphoma (r/r LBCL) as second-line therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-19.
Trial Details
NCT Number NCT07606937
Lead Sponsor Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Conditions Relapsed/Refractory Large B-cell Lymphoma
Enrollment 12 participants
Start Date 2026-06-12
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-05